In a recent study, an IFN-I-induced activation state of novel cDC1s was identified, which, unlike the conventional cross-presentation of cDC1s, can acquire and present intact tumor-derived peptide-MHC I complexes, thereby promoting a specific CD8+ antitumor response [147]. The gene discussed is CD8A; the disease is neoplasm.